# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

> **NCT02259959** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Single rising doses of BI 1744 CL, solution for oral inhalation
- **DRUG:** Tiotropium, fixed dose, solution for oral inhalation
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02259959
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02259959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02259959, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02259959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*